Monitoring musculoskeletal health in breast cancer patients on aromatase inhibitors
A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy
This study looks at how aromatase inhibitors affect the bone and joint health of postmenopausal women with hormone receptor-positive breast cancer to help improve their quality of life during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 870 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05921617 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on postmenopausal women with hormone receptor-positive breast cancer who are undergoing aromatase inhibitor therapy. It aims to monitor the musculoskeletal health of these patients, as the treatment is associated with significant musculoskeletal symptoms that can affect quality of life and treatment compliance. By tracking these symptoms, the study seeks to provide valuable insights for clinical practice and improve patient outcomes during endocrine therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are postmenopausal women with early-stage hormone receptor-positive breast cancer who have recently started aromatase inhibitor therapy.
Not a fit: Patients with breast cancer recurrence, distant metastasis, or other malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of musculoskeletal symptoms in breast cancer patients, enhancing their quality of life and adherence to treatment.
How similar studies have performed: While there is limited information on similar studies, the focus on musculoskeletal health in this context is relatively novel and may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Postoperative early breast cancer； 2. Hormone receptor-positive breast cancer diagnosed by pathology； 3. Aromatase inhibitor therapy (e.g., anastrozole, letrozole, exemestane) was initiated within 3 months; 4. Postmenopausal women, or premenopausal or perimenopausal women taking ovarian function inhibitors; 5. Informed consent and voluntary participation in the study. Exclusion Criteria: 1. Breast cancer recurrence or distant metastasis; 2. With other malignant tumors; 3. With cognitive or psychiatric disorders.
Where this trial is running
Shanghai, Shanghai
- School of Nursing, Fudan University — Shanghai, Shanghai, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.